ImmunoCore

STRIVE: Soluble T-cell receptor intervention towards viral eradication

The new study STRIVE is looking at an investigational medication for patients with HIV infection who are currently on an antiretroviral therapy (ART) regimen. This study will look at how safe the study drug is and how the body handles taking the study drug and how the study drug affects the body’s immune system.

The Chief Investigator at Imperial College is Professor Sarah Fidler and recruitment is at St Mary's Hospital in London and King's College London led by Dr Julie Fox.

STRIVE logo.jpg